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Edited by Gianni CesareniAbstract The regulatory b-subunit of protein kinase CK2
mediates the formation of the CK2 tetrameric form and it has
functions independent of CK2 catalytic subunit through interac-
tion with several intracellular proteins. Recently, we have shown
that CK2b associates with the human checkpoint kinase Chk1.
In this study, we show that Chk1 speciﬁcally phosphorylates in
vitro the regulatory b-subunit of CK2. Chymotryptic peptides
and mutational analyses have revealed that CK2b is phosphor-
ylated at Thr213. Formation of a stable complex between CK2b
and Chk1 is not aﬀected by the modiﬁcation of Thr213 but it
does require the presence of an active Chk1 kinase.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein kinase CK2 is a constitutively active enzyme, highly
conserved in all eukaryotic species so far investigated and es-
sential for viability.
The mammalian heterotetrameric form of CK2 consists of
two catalytic subunits (a and/or a0) and two regulatory b-
subunits. A signiﬁcant body of evidences indicates that CK2
regulates, through protein interaction and/or phosphorylation,
a wide variety of proteins involved in the control of various
aspects of cellular function, i.e., nucleic acid and protein syn-
thesis, cell cycle control, cell proliferation and tumorigenesis
[1–3]. Biosynthetic labeling studies have shown that CK2b is
synthesized in excess of CK2a and that the formation of CK2b
dimers precedes the interaction with the catalytic subunits for
the formation of the CK2 tetrameric form [4]. Moreover,
mounting evidences have suggested that CK2b exists in cells in
the absence of CK2 catalytic subunits indicating that this
protein has independent functions exerted through complex
formation with nuclear and cytoplasmic proteins [2,5,6]. Re-
cently, we have identiﬁed a new CK2b interacting protein: the
checkpoint kinase Chk1 [7]. Chk1 is a serine/threonine protein
kinase ﬁrst identiﬁed in S. pombe as an essential protein kinase
for G2 cell cycle arrest induced by DNA damage [8]. Chk1,* Corresponding author. Fax: +45-6550-2467.
E-mail address: bag@bmb.sdu.dk (B. Guerra).
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Chk2, is a key enzyme which coordinates cell cycle progression
and preserves genome integrity (for review see [9]). Targeted
disruption of mammalian Chk1 in mice shows that embryos
depleted of Chk1 exhibit morphological abnormalities in nu-
clei at the blastocyst stage and indicate that Chk1 is indis-
pensable for cell proliferation and survival through the
preservation of the G2 checkpoint [10,11]. Chk1 appears to be
an active enzyme even in the absence of DNA damage [12,13].
Cell cycle perturbation induced by DNA damage or stalled
replication leads to further activation of Chk1 kinase, which in
turn targets downstream proteins involved in the response to
genotoxic stress. To better elucidate the precise mechanisms
involved in Chk1 kinase regulation, we demonstrated that the
functional interaction between Chk1 and CK2b leads to en-
hanced Chk1 kinase activity with respect to Cdc25C phos-
phorylation [7].
In this report, we show evidence that the native and re-
combinant human Chk1 kinase phosphorylates the regulatory
b-subunit of CK2. Moreover, Chk1 does not target the cata-
lytic subunit of CK2 nor the CK2 holoenzyme indicating the
speciﬁcity of Chk1-catalyzed CK2b phosphorylation. In the
attempt to map CK2b phosphorylation site we have identiﬁed,
as a recognition residue, Thr213 which maps to the C-terminal
domain of CK2b protein.2. Materials and methods
2.1. Plasmid constructs
Human HA-tagged Chk1 plasmid was a gift from Clare Mc Gowan
(San Diego, CA, USA). CK2b-MycHis plasmid was cloned into
pcDNA3.1 vector (Invitrogen) as described previously [7]. CK2b
T213A-MycHis mutant was generated by PCR mutagenesis from wild-
type pcDNA3.1 CK2b-MycHis using the QuickChange site-directed
mutagenesis kit (Stratagene). The primers were the following: forward
primer 50-GAGCCCAGTCAAGGCGATTCGCTGA-30, reverse pri-
mer 50-TCAGCGAATCGCCTTGACTGGGCTC-30. The kinase-in-
active mutant of Chk1 (HA-Chk1KD) was generated substituting
Asp130 with Ala using as a template wild-type HA-Chk1-expressing
plasmid and the following primers: forward primer 50-ATTGGAA-
TAACTCACAGGGCTATTAAACCAGAAAATCTT-30, reverse
primer 50-AAGATTTTCTGGTTTAATAGCCCTGTGAGTTATTC-
CAAT-30. In all the constructs, the correct sequence and orientation
were veriﬁed by DNA sequencing.
2.2. Cell culture and transfection procedure
Cos-1 cell line was grown in Dulbecco’s MEM (Gibco) supple-
mented with 10% (v/v) fetal bovine serum at 37 C with 5% CO2. Cellsblished by Elsevier B.V. All rights reserved.
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to the manufacturer’s instructions. Cells were harvested after 48 h from
the beginning of transfection.
2.3. Preparation of cell extracts
Protein extracts from cells transiently overexpressing Chk1 and
CK2b were prepared as previously described [6] and subsequently
utilized for various experiments as indicated in Section 3.
2.4. Antibodies, immunoprecipitation and immunoblotting
The anti-Chk1 monoclonal antibody (G-4) was purchased from
Santa Cruz, the anti-HA monoclonal antibody was purchased from
Babco. Protein kinase CK2 a-subunit was detected with a mouse
monoclonal antibody (1AD9), CK2 b-subunit was detected with a
mouse monoclonal antibody (6D5) both purchased from Calbiochem.
Rabbit polyclonal anti-HA antibody (Y-11) and rabbit polyclonal
anti-Myc antibody (A-14) were purchased from Santa Cruz. Rabbit
polyclonal anti-CK2b antibody was obtained by immunizing rabbits
against the native protein.
Immunoprecipitation experiments and protein visualization were
performed essentially as described previously [6,7].
2.5. Puriﬁcation of recombinantly expressed proteins
The wild-type form of CK2b, the deletion mutant CK2b (1–155) and
the mutant CK2b T213A were cloned into pT7-7 vector and expressed
into the BL21(DE3) bacterial strain. The expression and puriﬁcation of
these proteins were performed as described previously [7]. CK2a and
CK2 holoenzyme were expressed and puriﬁed essentially as described
in [14]. Recombinant human GST-hChk1 was purchased from Upstate
Biotechnology, while GST-Cdc25C200–256 was expressed and puriﬁed
according to [7].
2.6. Protein kinase assays
Recombinant CK2a, CK2b, and CK2b mutants, CK2 holoenzyme
or GST-Cdc25C200–256 were incubated with recombinant GST-hChk1
in kinase buﬀer containing 50 mM Tris–HCl, pH 7.4, 1 mM DTT, 10
mM MgCl2, 50 lM ATP, 10 lCi [c-32P]ATP and 100 lM sodium
orthovanadate. Reaction mixtures (30 ll) were incubated 30 min at 30
C and analyzed by SDS–PAGE after adding SDS sample buﬀer. The
amounts of enzymes and proteins used in the assays are indicated in
the ﬁgure legends. In some experiments heparin from bovine lung
(Sigma) was added to a ﬁnal concentration of 0.05 lg/ll. Protein ex-
tracts from cells co-transfected with HA-Chk1 and CK2b-MycHis or
CK2b T213A-MycHis were utilized for co-immunoprecipitation ex-
periments using monoclonal anti-Chk1 antibody. Chk1 kinase assay
was performed in kinase buﬀer (ﬁnal volume 60 ll) for 30 min at 30 C.
Reactions were stopped by addition of SDS sample buﬀer. Phos-
phorylated proteins were separated by SDS–PAGE, transferred to a
PVDF membrane and visualized by autoradiography. The quantiﬁ-
cation of the phosphate incorporated into the substrate targets was
done by scintillation counting (Hewlett-Packard) of the excised ra-
dioactive bands. The kinase-inactive mutant of Chk1 (HA-Chk1KD)
was tested in an in vitro kinase assay (using GST-Cdc25C200–256 as a
substrate) after immunoprecipitation of Chk1 with polyclonal anti-HA
antibody from cells transfected with HA-Chk1KD plasmid.
2.7. Sample preparation for mass spectrometric analysis
5 lg CK2b was in vitro phosphorylated by Chk1 in a non-radio-
active kinase assay. Two gel bands, each representing 2.5 lg of CK2b,
were excised and the proteins were reduced in the gel using 10 mM
DTT in 0.1 M NH4HCO3 for 45 min at 56 C. The proteins were then
alkylated using 55 mM iodoacetamide in 0.1 M NH4HCO3 for 30 min.
Subsequently, in gel digestion was performed at 37 C overnight using
0.375 lg chymotrypsin (Worthington) in 50 mM NH4HCO3 as de-
scribed previously [15].
2.8. Liquid chromatography electrospray ionization tandem mass
spectrometry
In order to identify the CK2b residue(s) phosphorylated by Chk1, on-
line liquid chromatography electrospray ionization tandem mass
spectrometry (LC-ESI-MS/MS) analysis was performed. The analysis
and database searching was performed as described in [16] with the
following modiﬁcation: peptides were eluted using a linear gradient of
0–50% of buﬀer B (90% (v/v) acetonitrile, 1% (v/v) formic acid, 0.6% (v/
v) acetic acid and 0.005% (v/v) heptaﬂuorobutyric acid) in 40 min.3. Results
3.1. Checkpoint kinase Chk1 speciﬁcally phosphorylates the
regulatory b-subunit of protein kinase CK2
With an in vitro kinase assay using bacterially expressed
CK2b we could conﬁrm, as previously observed [7], that CK2b
is phosphorylated by recombinant Chk1 (Fig. 1A, lane 2) with a
stoichiometry of phosphate incorporation of 1.1 pmol/pmol of
CK2b substrate. A kinase assay performed in the presence of
equimolar amounts of CK2b and GST-Cdc25C200–256 showed
that despite the fact that Cdc25C is the favorite substrate for
Chk1 kinase, CK2b is a competitive, albeit weak, substrate for
Cdc25C: the phosphate incorporation in Cdc25C substrate is
reduced by 27% as compared to when CK2b is absent (Fig. 1A,
lanes 3 and 4). A phosphorylation assay with Chk1 performed
in the presence of constant amounts of CK2b (i.e., 100 pmol)
conﬁrmed the previous observation inasmuch that the phos-
phorylation of Cdc25C increases in relation to increasing
amounts of Cdc25C (i.e., from 50 pmol up to 300 pmol), while
the phosphorylation of CK2b decreases concomitantly
(Fig. 1B, lanes 1–4). Similarly to the experiment shown in
Fig. 1A, when increasing amounts of CK2b (i.e., from 50 pmol
up to 200 pmol) were added to a ﬁxed amount of Cdc25C (100
pmol), we did not observe a signiﬁcant decrease of Cdc25C
phosphorylation (results not shown). Next, we wanted to verify
whether Chk1 targets speciﬁcally and exclusively the regulatory
subunit of protein kinase CK2. We performed an in vitro ki-
nase assay using recombinant CK2a and CK2 holoenzyme as
additional Chk1 potential substrate targets. A speciﬁc inhibitor
of CK2, heparin, was used in some phosphorylation reactions
in order to eﬀectively block CK2 autophosphorylation activity.
Heparin is a highly speciﬁc polyanionic inhibitor of CK2 but
not of Chk1 kinase (Fig. 1C, lanes 1 and 2, [7]). As shown in
Fig. 1D, Chk1 kinase speciﬁcally phosphorylates CK2b-sub-
unit (Fig. 1D lane 8) but does not phosphorylate the catalytic a-
subunit of CK2 (Fig. 1D, lanes 3, 9 and 10). Interestingly, the
quantiﬁcation of incorporated radioactive phosphate revealed
that CK2b within the holoenzyme no longer represents a Chk1
substrate target (Fig. 1D, lanes 4, 5 and 11). In order to verify
the ability of the native form of Chk1 kinase to phosphorylate
CK2b, ectopically expressed HA-tagged Chk1 was co-immu-
noprecipitated with ectopically expressed CK2b-MycHis using
a monoclonal anti-Chk1 antibody (Fig. 2). The incubation of
the immune complex with a radioactive mix in an in vitro ki-
nase assay led to the phosphorylation of a protein that ap-
peared to be the exogenously expressed CK2b-subunit as
revealed by probing the Western blot membrane with a poly-
clonal anti-CK2b antibody.3.2. Chk1 kinase phosphorylates the regulatory b-subunit of
CK2 at its C-terminal domain
The determination of substrate speciﬁcity for human Chk1
by the oriented peptide library approach [17] has revealed that
Chk1 kinase has a strong preference for basic residues at the
)3 position and hydrophobic residues at the +1 position rel-
ative to the phosphorylated residue. Interestingly, a closer look
at the consensus sequence identiﬁed in several Chk1 substrate
targets has revealed that for some proteins, i.e., p53 and
Brca-1, there is a lack of a common motif. Taking that into
consideration, we attempted to identify all possible Chk1-
catalyzed CK2b phosphorylation sites (Fig. 3A). As shown in
Fig. 1. Chk1 kinase phosphorylates speciﬁcally CK2b in vitro. (A) In vitro kinase assay of GST-tagged Cdc25C200–256 (lanes 3 and 4) and re-
combinant CK2b (lanes 2 and 4) by recombinant GST-Chk1 kinase. The kinase assay was performed in the presence of equimolar amounts (96 pmol)
of GST-Cdc25C200–256 and CK2b and 2 pmol recombinant GST-Chk1 as a kinase source. (B) Chk1 kinase assay performed in the presence of in-
creasing amounts of GST-Cdc25C200–256 (lane 1, pmol; lane 2, pmol; lane 3, pmol; and lane 4, 300 pmol) and equal amounts of CK2b (lanes 1–4, 100
pmol). (C) Chk1 kinase assay performed in the absence or in the presence (lanes 1 and 2, respectively) of 50 ng/ll heparin using as substrate target
GST-Cdc25C200–256. (D) Autoradiograph showing the speciﬁc phosphorylation of CK2b by Chk1 kinase. Lanes 1, 2, 3 and 4 represent control
experiments where proteins were incubated in the presence of a radioactive mix. Lanes 6 and 7 represent also control experiments where CK2a and
CK2 holoenzymes were incubated in the presence of a radioactive mix containing heparin. Lanes 5, 8 and 9 show phosphorylation experiments where
CK2 holoenzyme, CK2b and CK2a, respectively, were incubated in the presence of Chk1 kinase. Lanes 10 and 11 are like lanes 9 and 5, respectively,
where samples were incubated in the presence of heparin. The data are representatives of three independent experiments.
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of CK2 as an isolated subunit but not when CK2b is in
complex with CK2a. Looking at the crystal structure of the
human CK2 holoenzyme [5], we speculated that CK2b phos-
phorylation site could reside in the C-terminal domain of
CK2b which, within the CK2 holoenzyme, makes contacts
with the distal b-subunit: a stretch unaccessible for Chk1-cat-alyzed CK2b phosphorylation. The possibility was tested by
an in vitro kinase assay using recombinant CK2b wild-type or
truncated CK2b (1–155) forms (Fig. 3B) as substrates and
recombinant Chk1 as a kinase source. As predicted, the C-
terminal truncated CK2b (1–155) did not show a phosphory-
lation comparable to the one observed with CK2b wild-type
(Fig. 3C, lanes 2 and 3).
Fig. 2. Speciﬁc phosphorylation of CK2b by Chk1 kinase in cells
transiently overexpressing both proteins. Cos-1 cells were transfected
with HA-Chk1 and CK2b-MycHis expressing plasmids. Total protein
lysate was subjected to immunoprecipitation with monoclonal anti-
Chk1 antibody. The precipitates were assayed for Chk1 kinase activity
using the co-precipitating CK2b as substrate target (lane 2). Lane 1
represents a control experiment performed in the presence of control
IgG antibodies. Samples were resolved by SDS–PAGE, analyzed by
Western blot and by autoradiography. Chk1 was detected with a
polyclonal anti-HA antibody and CK2b with an aﬃnity-puriﬁed
polyclonal antibody.
Fig. 3. Chk1 phosphorylates CK2b in the C-terminal domain. (A) Primar
phorylation sites targeted by Chk1 according to Chk1 consensus sequence. (B
(upper) or a deletion mutant (lower). (C) In vitro kinase assay of bacterially
(lane 3) using recombinant active GST-Chk1. Proteins were separated by S
visualizing phosphorylated CK2b. Proteins were revealed by probing the blo
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Chk1 at Thr213
Based on the previous results, the exact CK2b phosphory-
lation site was identiﬁed by mass spectrometry. Theoretical
enzymatic cleavages of CK2b using either of the serine pro-
teases, trypsin or chymotrypsin, were performed. The resulting
candidate peptides between residues 181 and 215 are shown in
Table 1. Initial analysis of tryptic or chymotryptic in-gel di-
gested peptides were performed using matrix assisted laser
desorption/ionization (MALDI) mass spectrometry. A peptide
with the m=z value of 1007.6 Da was observed in the chymo-
tryptic peptide mass map which could correspond to the 208–
215 peptide carrying one phosphorylation (data not shown).
Further investigations were performed using LC-ESI-MS/MS
in order to determine the exact phosphorylation site in the
1007.6 Da peptide. The search for phosphopeptides led to the
identiﬁcation of the 208-KSPVKTIR-215 peptide with a single
phosphorylation based on the observed mass (data not
shown). The MS/MS spectrum showing the fragmentation of
the doubly charged precursor ion (m=z 504.77) corresponding
to the phosphorylated peptide of interest was manually inter-y sequence of human CK2b. Arrows indicate the hypothetical phos-
) Schematic representation of the constructs encoding CK2b wild-type
expressed CK2b wild-type (lane 2) and CK2b (1–155) deletion mutant
DS–PAGE, transferred to PVDF membrane and exposed to ﬁlm for
ts with anti-CK2b and anti-Chk1 antibodies.
Table 1
Candidate peptides containing potential target serine or threonine
residues based on theoretical enzymatic cleavages using trypsin (upper)











MHþ is the monoisotopic mass over charge (m=z) value. Serines (S)
and threonines (T) are in bold.
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ylated residue, since the mass diﬀerence of 181 corresponds to
the mass of phosphothreonine (m=z 469.2–288.2). The frag-
ments caused by the loss of phosphoric acid by b-elimination
in the gas phase are indicated by horizontal arrows. The m=z
371.2 fragment ion originates from the b-elimination in the
gas phase of the phosphopeptide pTIR generating 2-amino-
dehydrobutyric acid bound to IR, the latter characterized by
the m=z 83 mass diﬀerence (371.2–288.2) [18] further conﬁrm-
ing the presence of the phosphate group on the threonine
residue.Fig. 4. The MS/MS spectrum of the double charged m=z 504.77 precursor ion
215. The punctuated vertical arrows indicate the singly charged fragment ions
sequence of the peptide. The horizontal arrows indicate the loss of H3PO4 (3.4. Chk1-mediated CK2b phosphorylation at Thr213 does not
aﬀect Chk1–CK2b complex formation but it does a Chk1
kinase-dead mutant
The identiﬁcation of Thr213 as CK2b residue phosphory-
lated by Chk1 kinase was veriﬁed by site directed mutagenesis.
A recombinant CK2b mutant was created where Thr213 was
exchanged for Ala (CK2b T231A). The mutated protein was
expressed and puriﬁed to homogeneity for in vitro phosphor-
ylation assays in the presence of recombinant Chk1 kinase. As
indicated in Fig. 5A, only CK2b wild-type could be extensively
phosphorylated by Chk1 (Fig. 5A, lane 4) but not CK2b
T213A (Fig. 5A, lane 5). Next, we veriﬁed the result described
above using native Chk1 kinase as a kinase source. Lysates
from transfected cells with HA-Chk1 plasmid were subjected
to immunoprecipitation with a polyclonal anti-HA antibody.
The immunoprecipitated Chk1 was then utilized as a kinase
source in an in vitro kinase assay. As shown in Fig. 5B, only
CK2b wild-type could be eﬃciently phosphorylated by native
Chk1 (Fig. 5B, lane 2), while no signiﬁcant phosphorylation
was observed with CK2b T231A mutant (Fig. 5B, lane 3). The
fact that CK2b is eﬃciently phosphorylated by Chk1 kinase
led us to verify whether the phosphorylation status of CK2b
played a role in the association between the two proteins. Cos-
1 cells were co-transfected with HA-Chk1 and CK2b-MycHis
or with HA-Chk1 and CK2b T213A-MycHis. Co-immuno-
precipitation experiments revealed that the phosphorylation of
CK2b at Thr213 is not necessary to allow the complex for-
mation (results not shown). Interestingly, immunoprecipita-
tion experiments performed with a polyclonal anti-CK2b
antibody on lysates of Cos-1 cells co-transfected with eithercorresponding to the singly phosphorylated peptide 208-KSPVKTIR-
and the amino acids between the punctuated vertical arrows verify the
)98 Da).
Fig. 5. Phosphorylation of CK2b at Thr213 is not required for the formation of a stable complex with Chk1. (A) In vitro kinase assay of CK2b (lanes
2 and 4) and CK2b T213A (lanes 3 and 5) in the presence of recombinant GST-Chk1 kinase. (B) Cos-1 cells were transiently transfected with HA-
Chk1 plasmid. Lysates were subjected to immunoprecipitation with polyclonal anti-HA antibody (lanes 2 and 3) or a control serum (lane 1). The
immunoprecipitated Chk1 was used as a kinase source for an assay in the presence of recombinant CK2b wild-type (lanes 1 and 2) or CK2b T231A
(lane 3) proteins. (C) Cos-1 cells were transfected with HA-Chk1 (lanes 1 and 2) or an inactive HA-Chk1 mutant (HA-Chk1KD, lane 3). Cell lysates
were subjected to immunoprecipitation with polyclonal anti-HA antibody (lanes 2 and 3) or a control serum (lane 1). The precipitated Chk1 kinase
was tested in an in vitro kinase assay using as a substrate GST-Cdc25C200–256. (D) Protein extracts from cells transfected with HA-Chk1 and CK2b-
MycHis or HA-Chk1KD and CK2b-MycHis plasmids were subjected to immunoprecipitation with rabbit polyclonal anti-CK2b antibody (lanes 2
and 3) or a control serum (lane 1). In all the experiments, proteins separated by SDS–PAGE and subsequently transferred to PVDF membrane were
exposed to ﬁlm and detected with speciﬁc antibodies.
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active mutant of Chk1 (HA-Chk1KD, Fig. 5C, lane 3) and
CK2b-MycHis, revealed that the ectopically expressed HA-
Chk1KD leads to a less stable interaction with CK2b (Fig. 5D,
lanes 2 and 3).4. Discussion
Protein kinase CK2 is a highly conserved enzyme involved in
many metabolic processes although its true intracellular role
remains unsolved and controversial. It is an essential kinase inyeast [19] and its dysregulated expression in transgenic mice
contributes to lymphocyte transformation [20], supporting the
idea that increased CK2 kinase activity correlates with tumor
development. Despite the fact that in vivo and in vitro CK2
exists mainly as a holoenzyme, increasing evidences suggest
that the subunits exist in vivo as isolated entities exerting
speciﬁc functions in complex with other cellular partners.
Undoubtedly, the regulatory b-subunit of CK2 plays a role in
many cellular events as it has been demonstrated by genetic
studies in S. cerevisiae and S. pombe (reviewed by [2]), in Xe-
roderma pigmentosum cell line [21] and in transgenic mice
where, in contrast to what occurs in yeast, CK2b is essential
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cently, we were able to show that CK2b interacts with the
human cell cycle checkpoint kinase Chk1 [7] enhancing its
kinase activity. In this study, we have shown that Chk1 spe-
ciﬁcally phosphorylates CK2b, as isolated subunit, at Thr213
although at present we cannot exclude the presence of other
minor site(s). The fact that CK2 holoenzyme does not con-
stitute a substrate target for Chk1 demonstrates that the CK2b
phosphorylation site at Thr213 is located in a structurally in-
accessible domain. Indeed, a careful analysis of CK2 tertiary
structure reveals that the CK2a=b contacts in the rhCK2
complex occur twice: through the so-called CK2b body do-
main of one rhCK2b molecule and the so-called CK2b tail (C-
domain) of the other rhCK2b subunit [5]. It is worth to
mention that the same CK2b C-terminal domain, where
Thr213 resides, is also the one involved in the complex for-
mation with Chk1 and that diﬀerent domains of CK2b have
been shown to be involved in protein-protein interactions. It
remains to be determined whether, in the sequence of CK2b,
these binding regions interact with diﬀerent proteins having a
regulatory signiﬁcance.
As shown in Section 3, the complex between CK2b and
Chk1 is not aﬀected by the modiﬁcation of CK2b at Thr213.
On the other hand, our results clearly show that a stable
complex formation requires the integrity of Chk1 kinase and
that the stability of the complex in intact cells may be under
the control of a conformationally active Chk1. Based on the
present data, a dual role of CK2b could be suggested: as a
substrate target of Chk1 which accounts for the competition
with other Chk1 substrates (i.e., Cdc25C) and as an activator
of Chk1 kinase presumably when in complex with the kinase.
The fact that under checkpoint activation there is no change in
Chk1–CK2b complex formation and that the CK2b-associated
Chk1 has considerable higher kinase activity [7], suggests that
the basal activity of Chk1 might be dependent on its interac-
tion with CK2b. One could speculate that defective Chk1
proteins, where Chk1–CK2b complex formation is attenuated
or impaired, might contribute to enhance genetic instability in
some tumors where cancer cells are less prone to activate
checkpoint signaling and to trigger apoptosis. At present, we
cannot exclude that Chk1-catalyzed CK2b phosphorylation
might aﬀect the interaction with other cellular proteins. A
careful examination of this complex during diﬀerent phases of
the cell cycle and the search for additional interacting partners
will help to better deﬁne the biological signiﬁcance of Chk1–
CK2b complex in further studies.Acknowledgements: We thank Jonna Jørgensen for excellent technical
assistance. This work was supported by the Danish Cancer Society
(Grant No. DP00035) to BAG.References
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